Table 1. Reported cases of pleural MALT lymphoma.
| No. | Ref. | Sex | Age, y | Initial symptoms | Radiological findings | IHC/FCM | BM infiltration | Treatment | Outcome | Nation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (6) | M | 79 | Pulmonary mass | Mass of L upper lobe & pleural nodules | IHC: CD20+, CD79a+ | No | NA | NA | Japan |
| 2 | (7) | M | 47 | Fever, chest pain | Consolidation of R lower lobe basal segment with a small hydrothorax | IHC: CD20+, IgM+ | No | Rejected | Stable disease | Canada |
| 3 | (8) | F | 67 | Dyspnea | Hydrothorax R-sided | FCM: CD20+, CD19+, CD79a+, IgM+ | Yes | Cladribine + RIX: 3 courses | Complete response | Japan |
| 4 | (9) | M | 79 | Back pain | Thickened mediastinum & pleura with hydrothorax R-sided | IHC: CD20+, CD79a+, CD45RO+, Bcl-2+ | NA | Surgery | NA | Japan |
| 5 | (10) | F | 65 | Pleural thickening | Thickened R pleura with hydrothorax | IHC: CD20+, CD79a+, CD3+ | No | RIX-CHOP: 6 courses | Complete response | Japan |
| 6 | (11) | F | 74 | Cough, fatigue | Thickened pleura with bulk hydrothorax R-sided | IHC: CD20+, kappa+ | No | RIX alone | Relapsed 2 y later | Japan |
| 7 | (12) | M | 52 | Pleura mass | Bulky mass in superior lobe of the R lung | IHC: CD20+, CD3+ | NA | NA | NA | Spain |
| 8 | (13) | M | 86 | No | Diffused thickness of parietal pleura | IHC: CD20+, CD79a+ | NA | NA | NA | Japan |
| 9 | (14) | F | 68 | Dyspnea | Nodular lesions of pleura with hydrothorax R-sided | IHC: CD20+, CD79a+, Bcl-2+ | Yes | RIX-CHOP | Hydrothorax disappeared | Japan |
| 10 | (15) | M | 76 | Hydrothorax | Diffused thickness of parietal pleura with hydrothorax R-sided | IHC: CD20+, CD79a+, CD5+ | NA | Surgery + IMCT (RIX-CHOP) | Hydrothorax significantly reduced | Japan |
| 11 | (16) | M | 64 | Cough, chest pain, dyspnea, fatigue, weight loss | Thickened pleura with bulk hydrothorax R-sided | IHC: CD20+ | No | IMCT (RIX-CHOP) + radiotherapy | Complete response | Tunisia |
| 12 | (17) | M | 39 | Abnormal signs on X-ray | Mass of R pleura, no hydrothorax | IHC: CD20+, CD79a+, Bcl-2+ | No | NA | NA | Japan |
| 13 | (18) | M | 71 | Dyspnea, cough, weight loss | Bulk hydrothorax R-sided | FCM: CD20+, CD19+, CD22+, CD3+, kappa+ | NA | Rejected | NA | U.S. |
| 14 | (19) | M | 71 | Hydrothorax | Hydrothorax L-sided | IHC: CD20+, CD19+, kappa+, Bcl-2+, MIB+ | NA | RIX alone | Alive after 5 y follow-up | Japan |
| 15 | (20) | M | 62 | Dyspnea & weight loss | Bulk bilateral hydrothorax with compressive pulmonary atelectasis | FCM: CD19+ | Yes | BR | Hydrothorax reduced | U.S. |
| 16 | This study | M | 54 | Cough & shortness of breath | Significant local thickened R pleura with hydrothorax R-sided | IHC: CD20+, CD3+, CD5+, CD23, CD21+, CD43+, CD7+, kappa+, Bcl-2+, PAX5+, MUM1+, ki67 10% | No | RIX-CHOP | Hydrothorax reduced | China |
MALT, mucosa-associated lymphoid tissue; IHC, immunohistochemistry; FCM, flow cytometry; BM, bone marrow; F, female; M, male; BR, bendamustine and rituximab; RIX, rituximab; CHOP, cyclophosphamide, epirubicin, vindesine, and prednisolone; IMCT, immunochemotherapy; NA, not available.